

**Table 3.1**  
**Verified Outcomes (Annualized Percentages) by Age at Enrollment for MRC Super Cohort Participants<sup>1</sup>**  
 Data as of: February 19, 2022; Events through February 19, 2022

Outcomes	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	44174	6788	9352	19418	8616
<b>Mean follow-up (months)</b>	189.8	206.4	206.5	190.7	156.6
<b>Cardiovascular</b>					
CHD <sup>2</sup>	4008 (0.57%)	287 (0.25%)	518 (0.32%)	1922 (0.62%)	1281 (1.14%)
CHD death <sup>3</sup>	1918 (0.27%)	93 (0.08%)	179 (0.11%)	881 (0.29%)	765 (0.68%)
Clinical MI	2618 (0.37%)	210 (0.18%)	387 (0.24%)	1288 (0.42%)	733 (0.65%)
Angina <sup>4</sup>	1625 (0.47%)	114 (0.20%)	226 (0.30%)	785 (0.52%)	500 (0.76%)
CABG/PTCA	3170 (0.45%)	277 (0.24%)	545 (0.34%)	1621 (0.53%)	727 (0.65%)
Carotid artery disease	537 (0.08%)	29 (0.02%)	88 (0.05%)	288 (0.09%)	132 (0.12%)
Congestive heart failure, WHI <sup>4</sup>	1246 (0.36%)	84 (0.15%)	145 (0.19%)	531 (0.35%)	486 (0.74%)
Heart failure, UNC <sup>5</sup>	3392 (0.65%)	219 (0.27%)	405 (0.34%)	1642 (0.70%)	1126 (1.25%)
Stroke	3334 (0.48%)	234 (0.20%)	427 (0.27%)	1655 (0.54%)	1018 (0.91%)
PAD	722 (0.10%)	51 (0.04%)	122 (0.08%)	369 (0.12%)	180 (0.16%)
DVT	1432 (0.20%)	141 (0.12%)	268 (0.17%)	680 (0.22%)	343 (0.31%)
Pulmonary embolism	1181 (0.17%)	126 (0.11%)	228 (0.14%)	557 (0.18%)	270 (0.24%)
DVT/PE	2100 (0.30%)	209 (0.18%)	397 (0.25%)	1006 (0.33%)	488 (0.43%)
Coronary disease <sup>6</sup>	8149 (1.17%)	637 (0.55%)	1168 (0.73%)	3901 (1.26%)	2443 (2.17%)
Aortic aneurysm <sup>7</sup>	79 (0.04%)	6 (0.02%)	13 (0.03%)	48 (0.05%)	12 (0.06%)
Valvular heart disease <sup>7</sup>	596 (0.30%)	45 (0.12%)	99 (0.19%)	333 (0.38%)	119 (0.55%)
<b>Total cardiovascular disease<sup>8</sup></b>	<b>11541 (1.65%)</b>	<b>868 (0.74%)</b>	<b>1669 (1.04%)</b>	<b>5529 (1.79%)</b>	<b>3475 (3.09%)</b>
<b>Cancer</b>					
Breast cancer	3094 (0.44%)	484 (0.41%)	718 (0.45%)	1392 (0.45%)	500 (0.44%)
Invasive breast cancer	2552 (0.37%)	381 (0.33%)	587 (0.36%)	1143 (0.37%)	441 (0.39%)
In-situ breast cancer	604 (0.09%)	112 (0.10%)	142 (0.09%)	283 (0.09%)	67 (0.06%)
Ovarian cancer	292 (0.04%)	30 (0.03%)	63 (0.04%)	147 (0.05%)	52 (0.05%)
Endometrial cancer <sup>9</sup>	351 (0.09%)	57 (0.09%)	92 (0.09%)	149 (0.08%)	53 (0.08%)
Colorectal cancer	1005 (0.14%)	95 (0.08%)	158 (0.10%)	497 (0.16%)	255 (0.23%)
Other cancer <sup>10</sup>	4561 (0.65%)	470 (0.40%)	862 (0.54%)	2231 (0.72%)	998 (0.89%)
<b>Total cancer</b>	<b>8578 (1.23%)</b>	<b>1052 (0.90%)</b>	<b>1757 (1.09%)</b>	<b>4052 (1.31%)</b>	<b>1717 (1.53%)</b>
<b>Fractures</b>					
Hip fracture	1813 (0.26%)	71 (0.06%)	179 (0.11%)	843 (0.27%)	720 (0.64%)
<b>Deaths</b>					
Cardiovascular deaths	4498 (0.64%)	197 (0.17%)	433 (0.27%)	2068 (0.67%)	1800 (1.60%)
Cancer deaths	3494 (0.50%)	291 (0.25%)	576 (0.36%)	1740 (0.56%)	887 (0.79%)
Other known cause	4668 (0.67%)	238 (0.20%)	539 (0.33%)	2290 (0.74%)	1601 (1.42%)
Unknown cause	107 (0.02%)	11 (0.01%)	14 (0.01%)	52 (0.02%)	30 (0.03%)
Not yet adjudicated	410 (0.06%)	37 (0.03%)	71 (0.04%)	242 (0.08%)	60 (0.05%)
<b>Total death<sup>11</sup></b>	<b>21236 (2.35%)</b>	<b>1242 (0.78%)</b>	<b>2613 (1.24%)</b>	<b>10129 (2.57%)</b>	<b>7252 (5.10%)</b>

<sup>1</sup> The MRC Super Cohort includes all WHI Hormone Trial participants and all Non-Hispanic Black/African American and Hispanic/Latina participants (identified from race/ethnicity collected on Form 2 at baseline) from the CT and OS.

<sup>2</sup> "CHD" includes clinical MI, evolving Q-wave MI, and CHD death; Q-wave MI is not collected in the WHI Extension Studies 2005-2025.

<sup>3</sup> "CHD death" includes definite and possible CHD death.

<sup>4</sup> Angina and CHF are not verified outcomes in the WHI Extension Studies 2005-2025. Reported statistics represent experience during the original program.

<sup>5</sup> Definite or possible decompensated heart failure adjudicated by UNC.

<sup>6</sup> "Coronary disease" includes clinical MI, evolving Q-wave MI, possible evolving Q-wave MI, CHD death, angina, congestive heart failure, UNC heart failure, and CABG/PTCA; Q-wave MI, angina, and congestive heart failure are not collected in the WHI Extension Studies 2005-2025.

<sup>7</sup> Aortic aneurysm and valvular heart disease are new adjudicated outcomes during the WHI Extension Study 2010-2025.

<sup>8</sup> Total CVD does not include aortic aneurysm or valvular heart disease.

<sup>9</sup> Only women without a baseline hysterectomy are used to compute the annual rates of endometrial cancer.

<sup>10</sup> Only one report of "other cancer" is counted per woman; however, the first of each type is adjudicated. Excludes non-melanoma skin cancer.

<sup>11</sup> Includes deaths for non-Extension study participants after the main WHI study close-out. Annualized rates incorporate additional follow-up from the NDI search.